Supplementary Table S1: Modified version of the Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA). This checklist was used as a guide for the rapid review to determine eligibility criteria, information sources, search strategy, study records, outcomes and prioritisation and data synthesis. Although an SR/MA was not conducted, PRISMA guidelines were followed, except for elements that did not apply to a RER. Numbers in brackets refer to the PRISMA guideline item number.

|  |  |
| --- | --- |
| Modified Guidelines | Excluded/modified in PRISMA guidelines adapted for RER  |
| Title |  |
| Report it as a Rapid Evidence Review (RER). [1] |  |
| Abstract |  |
| Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria; and synthesis methods; results; limitations; conclusions and implications of key findings. [2] |  |
| Introduction |  |
| Rationale: Describe the rationale for the review in the context of what is already known. [3]Objective: Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design. [4] |  |
| Methods |  |
| Protocol and Registration: Indicate if a review protocol exists, if and where it can be accessed. [5]Eligibility Criteria: Study characteristics, report characteristics, criteria for eligibility, rationale. [6] Information sources:Describe all information sources (e.g., databases with dates of coverage) in the search and date last searched. [7]Search:Present full electronic search strategy for at least one database for replication. [8] Study Selection: State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). [9]Data Collection Process: Describe method of extraction from reports, processes for obtaining and confirming data from investigators. [10]Data items: List and define all variables for which data were sought and any assumptions and simplifications made. [11]Critical Appraisal/Risk of Bias of Individual sources of evidence:Describe methods used for assessing risk of bias of individual studies, and how this information is to be used in any data synthesis. [12]Summary measures:State the principal summary measures (e.g., risk ratio, difference in means). [13]Synthesis of Results:Describe methods of handling data and combining results of studies if done, including measures of consistency. [14]Risk of bias across studies:Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). [15]Additional analyses:Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. [16] | Item 15 excluded; no assessment on risk of bias for cumulative evidence.Item 16 excluded; no methods of additional analyses to be done. |
| Results |  |
| Study Selection:Give numbers of study screened, assessed and included with reasons for exclusions at each stage – flow diagram [17]Study Characteristics:Present characteristics for which data was extracted and citations for each study. [18]Risk of bias within studies:Present data on risk of bias of each study and, if available, any outcome level assessment. [19] Result of Individual studies:For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. [20]Synthesis of Results: Present results of meta-analysis done, including confidence intervals and measures of consistency. [21]Risk of bias across studies:Present results of any assessment of risk of bias across studies. [22]Additional analysis:Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression. [23] | Item 19 excluded; no risk data to be collected on risk of bias of each study. Item 22 excluded; no assessment on risk of bias across studies.Item 23 excluded; no additional analyses to be done.  |
| Discussion |  |
| Summary of Evidence:Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). [24]Limitations:Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias) and address gaps in research. [25]Conclusions:Provide a general interpretation of the results in the context of other evidence, and implications for future research. [26] |  |
| Funding |  |
| Funding:Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. [27] | This research received no specific grant from any funding agency, commercial or not-for-profit sectors.  |